<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; THOR</title>
	<atom:link href="http://www.stockbloghub.com/tag/thor/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABMD) Abiomed Sees Positive USpella Device Data</title>
		<link>http://www.stockbloghub.com/2011/12/01/abmd-abiomed-sees-positive-uspella-device-data/87836</link>
		<comments>http://www.stockbloghub.com/2011/12/01/abmd-abiomed-sees-positive-uspella-device-data/87836#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:01:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87836</guid>
		<description><![CDATA[Massachusetts-based cardiac assist devices maker Abiomed (ABMD) reported encouraging clinical data from the prophylactic use of its Impella 2.5 cardiac pumps in complex coronary interventions. Results from the company’s USpella multi-center observational registry, published in the December edition of the Catheterization and Cardiovascular Interventions Journal, showed that patients receiving percutaneous revascularization with Impella 2.5 support achieved a statistically significant improvement in left ventricle ejection fraction (“LVEF”). LVEF is a measure of the amount of blood beingpumped out of the left ventricle (the main pumping chamber) with each beat. Moreover, there was a considerable improvement of the functional heart failure status in one or more New York Heart Association (“NYHA”) classes (classification representing stages of heart failure). The results further validate the effectiveness and viability of Impella 2.5. Abiomed recently published ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/abmd-abiomed-sees-positive-uspella-device-data/87836/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Technology Industry Stock Outlook &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069</link>
		<comments>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069#comments</comments>
		<pubDate>Fri, 18 Nov 2011 18:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87069</guid>
		<description><![CDATA[The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. The beleaguered U.S. implantable defibrillator market continues to bother cardiac devices makers, as reflected by sustained implant volume pressure. On the other hand, companies in the orthopedic domain remain affected by a still choppy reconstructive implant market as they faced sustained pressure across hip, knee and spine businesses in the third quarter (albeit to a lesser extent vis-à-vis the sequentially prior quarter). Although a number of these issues are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANF) Company News for May 19, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/19/anf-company-news-for-may-19-2011-corporate-summary/74500</link>
		<comments>http://www.stockbloghub.com/2011/05/19/anf-company-news-for-may-19-2011-corporate-summary/74500#comments</comments>
		<pubDate>Thu, 19 May 2011 20:26:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Apparel Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[Celldex Therapeutics Inc]]></category>
		<category><![CDATA[CLDX]]></category>
		<category><![CDATA[DPS]]></category>
		<category><![CDATA[Dr Pepper Snapple Group Inc.]]></category>
		<category><![CDATA[Eastman Kodak Company]]></category>
		<category><![CDATA[EK]]></category>
		<category><![CDATA[Heartware International Inc]]></category>
		<category><![CDATA[HTWR]]></category>
		<category><![CDATA[MAT]]></category>
		<category><![CDATA[Mattel Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[SPLS]]></category>
		<category><![CDATA[Staples Inc.]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74500</guid>
		<description><![CDATA[•    Abercrombie &#38; Fitch (NYSE:ANF) reported Q1 EPS of $0.27, surpassing the Zacks Consensus Estimate of $0.11 per share. Revenues for the quarter rose 22% year-over-year to $836.7 million, beating the Zacks Consensus Estimate of $783.0 million •    Board of directors of Dr Pepper Snapple Group (NYSE:DPS) declared a quarterly dividend of $0.32 per share of the company&#8217;s common stock. Compared with the previous year, the group’s dividend has increased 28% •    Regulatory filings showed Eastman Kodak Co&#8217;s (NYSE:EK) CEO and chief financial officer purchased 36,532 shares on May 13. CEO Antonio Perez said in a statement to employees that the recent stock purchase program shows the management&#8217;s faith in the future of the  photography icon •    Biopharma company Celldex Therapeutics Inc. (NASDAQ:CLDX) has valued a public offering of 10 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/19/anf-company-news-for-may-19-2011-corporate-summary/74500/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) Thoratec Corporation &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/02/15/thor-thoratec-corporation-bear-of-the-day/66961</link>
		<comments>http://www.stockbloghub.com/2011/02/15/thor-thoratec-corporation-bear-of-the-day/66961#comments</comments>
		<pubDate>Tue, 15 Feb 2011 14:52:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66961</guid>
		<description><![CDATA[We downgrade our rating for Thoratec Corp. (THOR) to Underperform. Fourth-quarter fiscal 2010 revenues and earnings both missed the Zacks Consensus Estimates. Although Thoratec is still a growing company, its single product line and small size make it a riskier proposition. HeartWare has filed a PMA for a similar device, which will end Thoratec&#8217;s dominance for the BTT indication in late 2011 or early 2012, leaving it more dependent on the DT indication. However, growth estimates for the DT segment tend to vary. A lack of clear visibility into the pipeline of next-generation VADs, and absence of defined milestones, further clouds the outlook. It appears that the early hyper-growth phase enjoyed by the company is now leading to more normalized growth. THORATEC CORP (THOR): Free Stock Analysis Report Zacks Investment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/15/thor-thoratec-corporation-bear-of-the-day/66961/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) Thoratec Corporation &#8211; Earnings per share came in 86% higher than the forecast</title>
		<link>http://www.stockbloghub.com/2009/01/29/thor-thoratec-corporation-earnings-per-share-came-in-86-higher-than-the-forecast/2424</link>
		<comments>http://www.stockbloghub.com/2009/01/29/thor-thoratec-corporation-earnings-per-share-came-in-86-higher-than-the-forecast/2424#comments</comments>
		<pubDate>Thu, 29 Jan 2009 23:48:35 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2424</guid>
		<description><![CDATA[Thoratec Corporation (THOR) is coming off of an excellent quarterly announcement that showed a spike in revenue and another earnings surprise. Shares are also benefiting from a newly formed level of support. Company Description Thoratec Corporation provides cardiac support devices for use by patients with acute or chronic heart failure. Some of the products will pump blood through the heart for prolonged periods of time in the event of cardiac arrest. The company is headquartered in Pleasanton, California, employs more than 1,000 people internationally, and carries a market cap of $1.36 billion. Another Earnings Surprise On Oct 30 Thoratec announced third quarter results including a 44% increase in revenues. Total revenues for the quarter were $80.8 million up from $56.1 million, one year ago. Earnings per share came in at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/29/thor-thoratec-corporation-earnings-per-share-came-in-86-higher-than-the-forecast/2424/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) Thoratec Corporation &#8211; 27% earnings growth projection</title>
		<link>http://www.stockbloghub.com/2009/01/26/thor-thoratec-corporation-27-earnings-growth-projection/2334</link>
		<comments>http://www.stockbloghub.com/2009/01/26/thor-thoratec-corporation-27-earnings-growth-projection/2334#comments</comments>
		<pubDate>Mon, 26 Jan 2009 19:42:41 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2334</guid>
		<description><![CDATA[Thoratec Corp.&#8217;s (THOR) share price has continued to move higher since originally being featured as a momentum stock in early December. A trend line that has been supporting prices for the last 3 months is now being pressured just above $29. Third-Quarter Results Thoratec&#8217;s recent price strength comes on the heels of the company&#8217;s solid third-quarter results, reported in late October. Revenue was up 44% to $80 million. Earnings came in at 13 cents per share, almost doubling analyst estimates of 7 cents. Analyst Estimates Analyst estimates have continued to tick higher over the last 3 months, with the current-year estimate up 7 cents to 45 cents per share. The next-year estimate is pegged at $57 cent, a 27% earnings growth projection. The Chart This stock has been fairly range ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/26/thor-thoratec-corporation-27-earnings-growth-projection/2334/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) Thoratec Corporation &#8211; handily beat analyst estimates last quarter</title>
		<link>http://www.stockbloghub.com/2008/12/04/thoratec-corporation-handily-beat-analyst-estimates-last-quarter/1574</link>
		<comments>http://www.stockbloghub.com/2008/12/04/thoratec-corporation-handily-beat-analyst-estimates-last-quarter/1574#comments</comments>
		<pubDate>Thu, 04 Dec 2008 17:35:40 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1574</guid>
		<description><![CDATA[Thoratec Corp. (THOR) recently swung into profitability from last year, reporting strong third-quarter results that were fueled by the release of a product that was approved by regulators for sale in April. Estimates are on the move and so is Thoratec&#8217;s share price. Company Description Thoratec Corporation provides cardiac support devices for use by patients with acute or chronic heart failure. The company is headquartered in Pleasanton, California, employs more than 1,000 people internationally, and carries a market cap of $1.36 billion. Industry Trend The healthcare and medical devices segments of the market have weathered the recent economic volatility better than many of their peers, carrying the benefit of less elastic demand. This dynamic was evident when Thoratec posted strong third-quarter results on Oct 31. Third-Quarter Results Revenue was up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/04/thoratec-corporation-handily-beat-analyst-estimates-last-quarter/1574/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) &#8211; Thoratec Corp &#8211; gross margin of 61.5%, up from 58.8% one year ago</title>
		<link>http://www.stockbloghub.com/2008/08/23/thor-thoratec-corp-gross-margin-of-615-up-from-588-one-year-ago/327</link>
		<comments>http://www.stockbloghub.com/2008/08/23/thor-thoratec-corp-gross-margin-of-615-up-from-588-one-year-ago/327#comments</comments>
		<pubDate>Sat, 23 Aug 2008 22:41:32 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[THOR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=327</guid>
		<description><![CDATA[Thoratec Corporation (THOR) recently posted impressive second-quarter results. The stock is trading near its 52-week high and showing strength, despite terrible news slamming other biotech firms earlier this month. Company Description Thoratec Corporation provides cardiac support devices for use by patients with acute or chronic heart failure. Some of the products will pump blood through the heart for prolonged periods of time in the event of cardiac arrest. The company is headquartered in Pleasanton, California, employs more than 1,000 people internationally, and carries a market cap of $1.36 billion. Revenue is Up 44% in Second Quarter Thoratec announce second-quarter results on July 31st, which included revenue of $82.6 million or a 44% year-over-year increase. Earnings per share rose to 15 cents, easily topping the consensus estimate and last quarter&#8217;s report, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/08/23/thor-thoratec-corp-gross-margin-of-615-up-from-588-one-year-ago/327/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

